-
1
-
-
0035755974
-
Histone deacetylases and cancer: Causes and therapies
-
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202.
-
(2001)
Nat Rev Cancer
, vol.1
, pp. 194-202
-
-
Marks, P.1
Rifkind, R.A.2
Richon, V.M.3
Breslow, R.4
Miller, T.5
Kelly, W.K.6
-
2
-
-
0036386359
-
Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation
-
Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res. 2002;86:41-65.
-
(2002)
Adv Cancer Res
, vol.86
, pp. 41-65
-
-
Lehrmann, H.1
Pritchard, L.L.2
Harel-Bellan, A.3
-
3
-
-
0035063182
-
Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin
-
Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 2001;10:693-698.
-
(2001)
Hum Mol Genet
, vol.10
, pp. 693-698
-
-
Wade, P.A.1
-
4
-
-
28644440158
-
Histone deacetylase inhibitors: Discovery and development as anticancer agents
-
Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497-1511.
-
(2005)
Expert Opin Investig Drugs
, vol.14
, pp. 1497-1511
-
-
Marks, P.A.1
Dokmanovic, M.2
-
5
-
-
3943054839
-
The Sir2 family of protein deacetylases
-
Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417-435.
-
(2004)
Annu Rev Biochem
, vol.73
, pp. 417-435
-
-
Blander, G.1
Guarente, L.2
-
6
-
-
0037067696
-
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family
-
Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 2002;277:25748-25755.
-
(2002)
J Biol Chem
, vol.277
, pp. 25748-25755
-
-
Gao, L.1
Cueto, M.A.2
Asselbergs, F.3
Atadja, P.4
-
7
-
-
0030798245
-
Histone acetylation in chromatin structure and transcription
-
Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349-352.
-
(1997)
Nature
, vol.389
, pp. 349-352
-
-
Grunstein, M.1
-
8
-
-
28044471827
-
Acetylation and deacetylation of non-histone proteins
-
Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15-23.
-
(2005)
Gene
, vol.363
, pp. 15-23
-
-
Glozak, M.A.1
Sengupta, N.2
Zhang, X.3
Seto, E.4
-
9
-
-
34547864236
-
Histone deacetylase inhibitors: Molecular mechanisms of action
-
Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541-5552.
-
(2007)
Oncogene
, vol.26
, pp. 5541-5552
-
-
Xu, W.S.1
Parmigiani, R.B.2
Marks, P.A.3
-
10
-
-
0034045040
-
Histone deacetylases, transcriptional control, and cancer
-
Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000;184:1-16.
-
(2000)
J Cell Physiol
, vol.184
, pp. 1-16
-
-
Cress, W.D.1
Seto, E.2
-
12
-
-
1842631408
-
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer
-
Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59:177-189.
-
(2004)
Prostate
, vol.59
, pp. 177-189
-
-
Halkidou, K.1
Gaughan, L.2
Cook, S.3
Leung, H.Y.4
Neal, D.E.5
Robson, C.N.6
-
13
-
-
0035676731
-
Expression profile of histone deacetylase 1 in gastric cancer tissues
-
Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001;92: 1300-1304.
-
(2001)
Jpn J Cancer Res
, vol.92
, pp. 1300-1304
-
-
Choi, J.H.1
Kwon, H.J.2
Yoon, B.I.3
-
14
-
-
33744956666
-
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
-
Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281:13548-13558.
-
(2006)
J Biol Chem
, vol.281
, pp. 13548-13558
-
-
Wilson, A.J.1
Byun, D.S.2
Popova, N.3
-
15
-
-
26244441525
-
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
-
Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat. 2005;94:11-16.
-
(2005)
Breast Cancer Res Treat
, vol.94
, pp. 11-16
-
-
Zhang, Z.1
Yamashita, H.2
Toyama, T.3
-
16
-
-
2342603414
-
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
-
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5:455-463.
-
(2004)
Cancer Cell
, vol.5
, pp. 455-463
-
-
Zhu, P.1
Martin, E.2
Mengwasser, J.3
Schlag, P.4
Janssen, K.P.5
Gottlicher, M.6
-
17
-
-
17144378591
-
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
-
Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005;12:395-404.
-
(2005)
Cell Death Differ
, vol.12
, pp. 395-404
-
-
Huang, B.H.1
Laban, M.2
Leung, C.H.3
-
18
-
-
21044447215
-
Increased expression of histone deacetylase 2 is found in human gastric cancer
-
Song J, Noh JH, Lee JH, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005;113:264-268.
-
(2005)
APMIS
, vol.113
, pp. 264-268
-
-
Song, J.1
Noh, J.H.2
Lee, J.H.3
-
19
-
-
33644856123
-
Epigenetic therapy of cancer: Past, present and future
-
Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37-50.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 37-50
-
-
Yoo, C.B.1
Jones, P.A.2
-
20
-
-
1542588471
-
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
-
Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A. 1996;93:5705-5708.
-
(1996)
Proc Natl Acad Sci U S A
, vol.93
, pp. 5705-5708
-
-
Richon, V.M.1
Webb, Y.2
Merger, R.3
-
21
-
-
36148950997
-
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
-
Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247-1252.
-
(2007)
Oncologist
, vol.12
, pp. 1247-1252
-
-
Mann, B.S.1
Johnson, J.R.2
Cohen, M.H.3
Justice, R.4
Pazdur, R.5
-
22
-
-
33847258674
-
Discovery and development of SAHA as an anticancer agent
-
Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351-1356.
-
(2007)
Oncogene
, vol.26
, pp. 1351-1356
-
-
Marks, P.A.1
-
23
-
-
0028116705
-
Inducing differentiation of transformed cells with hybrid polar compounds: A cell cycle-dependent process
-
Marks PA, Richon VM, Kiyokawa H, Rifkind RA. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci U S A. 1994;91: 10251-10254.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 10251-10254
-
-
Marks, P.A.1
Richon, V.M.2
Kiyokawa, H.3
Rifkind, R.A.4
-
24
-
-
0027255759
-
Polar/apolar compounds induce leukemia cell differentiation by modulating cell-surface potential
-
Arcangeli A, Carla M, Del Bene MR, Becchetti A, Wanke E, Olivotto M. Polar/apolar compounds induce leukemia cell differentiation by modulating cell-surface potential. Proc Natl Acad Sci U S A. 1993;90: 5858-5862.
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, pp. 5858-5862
-
-
Arcangeli, A.1
Carla, M.2
del Bene, M.R.3
Becchetti, A.4
Wanke, E.5
Olivotto, M.6
-
25
-
-
0021980514
-
Molecular and cellular mechanisms of leukemic hemopoietic cell differentiation: An analysis of the Friend system
-
Tsiftsoglou AS, Wong W. Molecular and cellular mechanisms of leukemic hemopoietic cell differentiation: an analysis of the Friend system. Anticancer Res. 1985;5:81-99.
-
(1985)
Anticancer Res
, vol.5
, pp. 81-99
-
-
Tsiftsoglou, A.S.1
Wong, W.2
-
26
-
-
0026446246
-
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A phase II clinical trial with a differentiation-inducing agent
-
Andreeff M, Stone R, Michaeli J, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 1992;80:2604-2609.
-
(1992)
Blood
, vol.80
, pp. 2604-2609
-
-
Andreeff, M.1
Stone, R.2
Michaeli, J.3
-
27
-
-
0032539890
-
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
-
Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998;95:3003-3007.
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, pp. 3003-3007
-
-
Richon, V.M.1
Emiliani, S.2
Verdin, E.3
-
28
-
-
73949128107
-
Histone deacetylase inhibitors in cancer therapy
-
Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459-5468.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5459-5468
-
-
Lane, A.A.1
Chabner, B.A.2
-
29
-
-
0024996768
-
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
-
Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174-17179.
-
(1990)
J Biol Chem
, vol.265
, pp. 17174-17179
-
-
Yoshida, M.1
Kijima, M.2
Akita, M.3
Beppu, T.4
-
30
-
-
33748063974
-
A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
-
Giles F, Fischer T, Cortes J, et al. A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628-4635.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 4628-4635
-
-
Giles, F.1
Fischer, T.2
Cortes, J.3
-
31
-
-
51649126841
-
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
-
Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14:4500-4510.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4500-4510
-
-
Ellis, L.1
Pan, Y.2
Smyth, G.K.3
-
32
-
-
70349194470
-
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma
-
Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol. 2009;147: 97-101.
-
(2009)
Br J Haematol
, vol.147
, pp. 97-101
-
-
Dickinson, M.1
Ritchie, D.2
Deangelo, D.J.3
-
33
-
-
79960197509
-
A Phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma
-
Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. A Phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011;29:451-455.
-
(2011)
Cancer Invest
, vol.29
, pp. 451-455
-
-
Hainsworth, J.D.1
Infante, J.R.2
Spigel, D.R.3
Arrowsmith, E.R.4
Boccia, R.V.5
Burris, H.A.6
-
34
-
-
77951884767
-
A Phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
-
Rathkopf D, Wong BY, Ross RW, et al. A Phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2010;66:181-189.
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, pp. 181-189
-
-
Rathkopf, D.1
Wong, B.Y.2
Ross, R.W.3
-
35
-
-
49349104503
-
A Phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
-
Gimsing P, Hansen M, Knudsen LM, et al. A Phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81:170-176.
-
(2008)
Eur J Haematol
, vol.81
, pp. 170-176
-
-
Gimsing, P.1
Hansen, M.2
Knudsen, L.M.3
-
36
-
-
38949146399
-
A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
-
Steele NL, Plumb JA, Vidal L, et al. A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008;14:804-810.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 804-810
-
-
Steele, N.L.1
Plumb, J.A.2
Vidal, L.3
-
37
-
-
79956325272
-
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors
-
Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29:2052-2059.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2052-2059
-
-
Giaccone, G.1
Rajan, A.2
Berman, A.3
-
38
-
-
77952585540
-
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
-
Mackay HJ, Hirte H, Colgan T, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010;46:1573-1579.
-
(2010)
Eur J Cancer
, vol.46
, pp. 1573-1579
-
-
Mackay, H.J.1
Hirte, H.2
Colgan, T.3
-
39
-
-
61549123363
-
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
-
Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009;4:97-101.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 97-101
-
-
Ramalingam, S.S.1
Belani, C.P.2
Ruel, C.3
-
40
-
-
0036735385
-
FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases
-
Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62:4916-4921.
-
(2002)
Cancer Res
, vol.62
, pp. 4916-4921
-
-
Furumai, R.1
Matsuyama, A.2
Kobashi, N.3
-
41
-
-
79960185557
-
Romidepsin (Istodax, NSC-630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma
-
VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC-630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011;64:525-531.
-
(2011)
J Antibiot (Tokyo)
, vol.64
, pp. 525-531
-
-
Vandermolen, K.M.1
McCulloch, W.2
Pearce, C.J.3
Oberlies, N.H.4
-
42
-
-
19944432566
-
A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
-
Byrd JC, Marcucci G, Parthun MR, et al. A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959-967.
-
(2005)
Blood
, vol.105
, pp. 959-967
-
-
Byrd, J.C.1
Marcucci, G.2
Parthun, M.R.3
-
43
-
-
33749049594
-
A Phase II study of depsipeptide in refractory metastatic renal cell cancer
-
Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5:57-60.
-
(2006)
Clin Genitourin Cancer
, vol.5
, pp. 57-60
-
-
Stadler, W.M.1
Margolin, K.2
Ferber, S.3
McCulloch, W.4
Thompson, J.A.5
-
44
-
-
40749101544
-
Clinical and molecular responses in lung cancer patients receiving romidepsin
-
Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin Cancer Res. 2008;14:188-198.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 188-198
-
-
Schrump, D.S.1
Fischette, M.R.2
Nguyen, D.M.3
-
45
-
-
77958185126
-
Cancer and Leukemia Group B. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)
-
Otterson GA, Hodgson L, Pang H, Vokes EE; Cancer and Leukemia Group B. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010;5:1644-1648.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1644-1648
-
-
Otterson, G.A.1
Hodgson, L.2
Pang, H.3
Vokes, E.E.4
-
46
-
-
38949144400
-
Tolerability, pharmacodynamics, and pharmacokinetic studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
-
Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetic studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008;14:826-832.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 826-832
-
-
Klimek, V.M.1
Fircanis, S.2
Maslak, P.3
-
47
-
-
68649119641
-
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336)
-
Whitehead RP, Rankin C, Hoff PM, et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2009;27:469-475.
-
(2009)
Invest New Drugs
, vol.27
, pp. 469-475
-
-
Whitehead, R.P.1
Rankin, C.2
Hoff, P.M.3
-
48
-
-
70549105748
-
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
-
Molife LR, Attard G, Fong PC, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010;21:109-113.
-
(2010)
Ann Oncol
, vol.21
, pp. 109-113
-
-
Molife, L.R.1
Attard, G.2
Fong, P.C.3
-
49
-
-
78650992102
-
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
-
Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117:336-342.
-
(2011)
Cancer
, vol.117
, pp. 336-342
-
-
Niesvizky, R.1
Ely, S.2
Mark, T.3
-
50
-
-
79959956310
-
A Phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
-
Iwamoto FM, Lamborn KR, Kuhn JG, et al. A Phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011;13:509-516.
-
(2011)
Neuro Oncol
, vol.13
, pp. 509-516
-
-
Iwamoto, F.M.1
Lamborn, K.R.2
Kuhn, J.G.3
-
51
-
-
21244458052
-
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
-
Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23:3912-3922.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3912-3922
-
-
Ryan, Q.C.1
Headlee, D.2
Acharya, M.3
-
52
-
-
51649091668
-
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
-
Gore L, Rothenberg ML, O'Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008;14:4517-4525.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4517-4525
-
-
Gore, L.1
Rothenberg, M.L.2
O'Bryant, C.L.3
-
53
-
-
33947581039
-
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
-
Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007;109:2781-2790.
-
(2007)
Blood
, vol.109
, pp. 2781-2790
-
-
Gojo, I.1
Jiemjit, A.2
Trepel, J.B.3
-
54
-
-
58149377828
-
Multicenter Phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)- carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
-
Hauschild A, Trefzer U, Garbe C, et al. Multicenter Phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)- carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 2008;18:274-278.
-
(2008)
Melanoma Res
, vol.18
, pp. 274-278
-
-
Hauschild, A.1
Trefzer, U.2
Garbe, C.3
-
55
-
-
78650848615
-
Histone deacetylase inhibitors in the treatment of lymphoma
-
Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med. 2010;10:462-470.
-
(2010)
Discov Med
, vol.10
, pp. 462-470
-
-
Lemoine, M.1
Younes, A.2
-
56
-
-
0037158513
-
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications
-
Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673-5683.
-
(2002)
Oncogene
, vol.21
, pp. 5673-5683
-
-
Mitsiades, C.S.1
Mitsiades, N.2
Poulaki, V.3
-
57
-
-
9144220841
-
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
-
Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci U S A. 2004;101:540-545.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 540-545
-
-
Mitsiades, C.S.1
Mitsiades, N.S.2
McMullan, C.J.3
-
58
-
-
34948830177
-
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
-
Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood. 2007;110:2667-2673.
-
(2007)
Blood
, vol.110
, pp. 2667-2673
-
-
Kawamata, N.1
Chen, J.2
Koeffler, H.P.3
-
59
-
-
33847372445
-
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects on gene expression and growth of glioma cells in vitro and in vivo
-
Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res. 2007;13: 1045-1052.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1045-1052
-
-
Yin, D.1
Ong, J.M.2
Hu, J.3
-
60
-
-
0842277812
-
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
-
Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A. 2004;101:1241-1246.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 1241-1246
-
-
Gui, C.Y.1
Ngo, L.2
Xu, W.S.3
Richon, V.M.4
Marks, P.A.5
-
61
-
-
0034730127
-
Histone deacetylase inhibitor selectively induces p21WAF1 expression and geneassociated histone acetylation
-
Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and geneassociated histone acetylation. Proc Natl Acad Sci U S A. 2000;97: 10014-10019.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 10014-10019
-
-
Richon, V.M.1
Sandhoff, T.W.2
Rifkind, R.A.3
Marks, P.A.4
-
62
-
-
85047699941
-
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
-
Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21:427-436.
-
(2002)
Oncogene
, vol.21
, pp. 427-436
-
-
Deroanne, C.F.1
Bonjean, K.2
Servotte, S.3
-
63
-
-
22844432021
-
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors
-
Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005;280:26729-26734.
-
(2005)
J Biol Chem
, vol.280
, pp. 26729-26734
-
-
Bali, P.1
Pranpat, M.2
Bradner, J.3
-
64
-
-
34548075217
-
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: A result of hyperacetylation and inhibition of chaperone function of heat shock protein 90
-
Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res. 2007;13:4882-4890.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4882-4890
-
-
Fiskus, W.1
Ren, Y.2
Mohapatra, A.3
-
65
-
-
34047137143
-
The diagnosis, staging, and treatment options for mycosis fungoides
-
Keehn CA, Belongie IP, Shistik G, Fenske NA, Glass LF. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007;14:102-111.
-
(2007)
Cancer Control
, vol.14
, pp. 102-111
-
-
Keehn, C.A.1
Belongie, I.P.2
Shistik, G.3
Fenske, N.A.4
Glass, L.F.5
-
66
-
-
0016773923
-
Cutaneous T-cell lymphomas: The Sézary syndrome, mycosis fungoides, and related disorders
-
Lutzner AM, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med. 1975;83:534-552.
-
(1975)
Ann Intern Med
, vol.83
, pp. 534-552
-
-
Lutzner, A.M.1
Edelson, R.2
Schein, P.3
Green, I.4
Kirkpatrick, C.5
Ahmed, A.6
-
67
-
-
79958708461
-
Therapeutic advances in cutaneous T-cell lymphoma
-
Akilov OE, Geskin L. Therapeutic advances in cutaneous T-cell lymphoma. Skin Therapy Lett. 2011;16:1-5.
-
(2011)
Skin Therapy Lett
, vol.16
, pp. 1-5
-
-
Akilov, O.E.1
Geskin, L.2
-
68
-
-
21244464349
-
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
-
Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923-3931.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3923-3931
-
-
Kelly, W.K.1
O'Connor, O.A.2
Krug, L.M.3
-
69
-
-
70149124715
-
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
-
Fujiwara Y, Yamamoto N, Yamada Y, et al. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci. 2009;100:1728-1734.
-
(2009)
Cancer Sci
, vol.100
, pp. 1728-1734
-
-
Fujiwara, Y.1
Yamamoto, N.2
Yamada, Y.3
-
70
-
-
33845996135
-
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
-
Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31-39.
-
(2007)
Blood
, vol.109
, pp. 31-39
-
-
Duvic, M.1
Talpur, R.2
Ni, X.3
-
71
-
-
34547683194
-
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
-
Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-3115.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3109-3115
-
-
Olsen, E.A.1
Kim, Y.H.2
Kuzel, T.M.3
-
72
-
-
70349633604
-
A phase 2 study of vorinostat in acute myeloid leukemia
-
Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009;94:1375-1382.
-
(2009)
Haematologica
, vol.94
, pp. 1375-1382
-
-
Schaefer, E.W.1
Loaiza-Bonilla, A.2
Juckett, M.3
-
73
-
-
43049092663
-
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
-
Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19:964-969.
-
(2008)
Ann Oncol
, vol.19
, pp. 964-969
-
-
Crump, M.1
Coiffier, B.2
Jacobsen, E.D.3
-
74
-
-
39749103428
-
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
-
Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49(3):502-507.
-
(2008)
Leuk Lymphoma
, vol.49
, Issue.3
, pp. 502-507
-
-
Richardson, P.1
Mitsiades, C.2
Colson, K.3
-
75
-
-
71849117270
-
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a Phase I trial in follicular and mantle cell lymphoma
-
Watanabe T, Kato H, Kobayashi Y, et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a Phase I trial in follicular and mantle cell lymphoma. Cancer Sci. 2010;101:196-200.
-
(2010)
Cancer Sci
, vol.101
, pp. 196-200
-
-
Watanabe, T.1
Kato, H.2
Kobayashi, Y.3
-
76
-
-
79952773321
-
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
-
Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:1198-1203.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1198-1203
-
-
Kirschbaum, M.1
Frankel, P.2
Popplewell, L.3
-
77
-
-
38149140216
-
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
-
Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008;26:81-87.
-
(2008)
Invest New Drugs
, vol.26
, pp. 81-87
-
-
Blumenschein Jr., G.R.1
Kies, M.S.2
Papadimitrakopoulou, V.A.3
-
78
-
-
43049091153
-
Gynecologic Oncology Group. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
-
Modesitt SC, Sill M, Hoffman JS, Bender DP; Gynecologic Oncology Group. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182-186.
-
(2008)
Gynecol Oncol
, vol.109
, pp. 182-186
-
-
Modesitt, S.C.1
Sill, M.2
Hoffman, J.S.3
Bender, D.P.4
-
79
-
-
50249095068
-
Early Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
-
Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008;26:483-488.
-
(2008)
Invest New Drugs
, vol.26
, pp. 483-488
-
-
Vansteenkiste, J.1
van Cutsem, E.2
Dumez, H.3
-
80
-
-
72249110437
-
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
-
Bradley D, Rathkopf D, Dunn R, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer. 2009;115:5541-5549.
-
(2009)
Cancer
, vol.115
, pp. 5541-5549
-
-
Bradley, D.1
Rathkopf, D.2
Dunn, R.3
-
81
-
-
67649399669
-
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A Wisconsin Oncology Network Phase II study
-
Traynor AM, Dubey S, Eickhoff JC, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. J Thorac Oncol. 2009;4:522-526.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 522-526
-
-
Traynor, A.M.1
Dubey, S.2
Eickhoff, J.C.3
-
82
-
-
65349141942
-
Phase II trial of vorinostat in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study
-
Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol. 2009;27:2052-2058.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2052-2058
-
-
Galanis, E.1
Jaeckle, K.A.2
Maurer, M.J.3
-
83
-
-
58149242889
-
A Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study
-
Luu TH, Morgan RJ, Leong L, et al. A Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008;14:7138-7142.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7138-7142
-
-
Luu, T.H.1
Morgan, R.J.2
Leong, L.3
-
84
-
-
0042905956
-
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines
-
Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2003;2:151-163.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 151-163
-
-
Glaser, K.B.1
Staver, M.J.2
Waring, J.F.3
Stender, J.4
Ulrich, R.G.5
Davidsen, S.K.6
-
85
-
-
77649183822
-
A Phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
-
Wilson PM, El-Khoueiry A, Iqbal S, et al. A Phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010;65:979-988.
-
(2010)
Cancer Chemother Pharmacol
, vol.65
, pp. 979-988
-
-
Wilson, P.M.1
El-Khoueiry, A.2
Iqbal, S.3
-
86
-
-
77954692325
-
A Phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors
-
Fakih MG, Fetterly G, Egorin MJ, et al. A Phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res. 2010;16:3786-3794.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3786-3794
-
-
Fakih, M.G.1
Fetterly, G.2
Egorin, M.J.3
-
87
-
-
65649107307
-
A Phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer
-
Fakih MG, Pendyala L, Fetterly G, et al. A Phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res. 2009;15:3189-3195.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3189-3195
-
-
Fakih, M.G.1
Pendyala, L.2
Fetterly, G.3
-
88
-
-
0242610850
-
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA
-
Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003;63:7291-7300.
-
(2003)
Cancer Res
, vol.63
, pp. 7291-7300
-
-
Kim, M.S.1
Blake, M.2
Baek, J.H.3
Kohlhagen, G.4
Pommier, Y.5
Carrier, F.6
-
89
-
-
0037161744
-
HDAC6 is a microtubuleassociated deacetylase
-
Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubuleassociated deacetylase. Nature. 2002;417:455-458.
-
(2002)
Nature
, vol.417
, pp. 455-458
-
-
Hubbert, C.1
Guardiola, A.2
Shao, R.3
-
90
-
-
34250696097
-
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
-
Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007;13:3605-3610.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3605-3610
-
-
Ramalingam, S.S.1
Parise, R.A.2
Ramanathan, R.K.3
-
91
-
-
73949140461
-
Carboplatin and paclitaxel in combination with either vorinostat or placebo for firstline therapy of advanced non-small-cell lung cancer
-
Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for firstline therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:56-62.
-
(2010)
J Clin Oncol
, vol.28
, pp. 56-62
-
-
Ramalingam, S.S.1
Maitland, M.L.2
Frankel, P.3
-
92
-
-
79960066445
-
Proteostasis regulation at the endoplasmic reticulum: A new perturbation site for targeted cancer therapy
-
Liu Y, Ye Y. Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell Res. 2011;21:867-883.
-
(2011)
Cell Res
, vol.21
, pp. 867-883
-
-
Liu, Y.1
Ye, Y.2
-
93
-
-
84859455667
-
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically
-
September 2, 2011. [Epub ahead of print.]
-
Sato A, Asano T, Ito K, Sumitomo M, Asano T. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int. September 2, 2011. [Epub ahead of print.]
-
BJU Int
-
-
Sato, A.1
Asano, T.2
Ito, K.3
Sumitomo, M.4
Asano, T.5
-
94
-
-
68749093915
-
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis
-
Zhang QL, Wang L, Zhang YW, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia. 2009;23:1507-1514.
-
(2009)
Leukemia
, vol.23
, pp. 1507-1514
-
-
Zhang, Q.L.1
Wang, L.2
Zhang, Y.W.3
-
95
-
-
0242493856
-
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571
-
Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 2003;102:3765-3774.
-
(2003)
Blood
, vol.102
, pp. 3765-3774
-
-
Yu, C.1
Rahmani, M.2
Conrad, D.3
Subler, M.4
Dent, P.5
Grant, S.6
-
96
-
-
38049126172
-
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
-
Heider U, von Metzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol. 2008;80:133-142.
-
(2008)
Eur J Haematol
, vol.80
, pp. 133-142
-
-
Heider, U.1
von Metzler, I.2
Kaiser, M.3
-
97
-
-
34249993174
-
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib
-
Emanuele S, Lauricella M, Carlisi D, et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis. 2007;12:1327-1338.
-
(2007)
Apoptosis
, vol.12
, pp. 1327-1338
-
-
Emanuele, S.1
Lauricella, M.2
Carlisi, D.3
-
98
-
-
69349097803
-
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma
-
Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res. 2009;15:5250-5257.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5250-5257
-
-
Badros, A.1
Burger, A.M.2
Philip, S.3
-
99
-
-
82955170653
-
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
-
Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011;130:437-447.
-
(2011)
Breast Cancer Res Treat
, vol.130
, pp. 437-447
-
-
Thomas, S.1
Thurn, K.T.2
Biçaku, E.3
Marchion, D.C.4
Münster, P.N.5
-
100
-
-
79958084461
-
A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
-
Munster PN, Thurn KT, Thomas S, et al. A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104:1828-1835.
-
(2011)
Br J Cancer
, vol.104
, pp. 1828-1835
-
-
Munster, P.N.1
Thurn, K.T.2
Thomas, S.3
-
101
-
-
80052927231
-
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy
-
Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011;117:4424-4438.
-
(2011)
Cancer
, vol.117
, pp. 4424-4438
-
-
Chen, M.Y.1
Liao, W.S.2
Lu, Z.3
-
102
-
-
79952710830
-
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas
-
Stathis A, Hotte SJ, Chen EX, et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res. 2011;17: 1582-1590.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1582-1590
-
-
Stathis, A.1
Hotte, S.J.2
Chen, E.X.3
|